These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. Emran AA; Chatterjee A; Rodger EJ; Tiffen JC; Gallagher SJ; Eccles MR; Hersey P Trends Immunol; 2019 Apr; 40(4):328-344. PubMed ID: 30853334 [TBL] [Abstract][Full Text] [Related]
25. Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. Smithy JW; Moore LM; Pelekanou V; Rehman J; Gaule P; Wong PF; Neumeister VM; Sznol M; Kluger HM; Rimm DL J Immunother Cancer; 2017; 5():25. PubMed ID: 28331615 [TBL] [Abstract][Full Text] [Related]
26. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Dammeijer F; van Gulijk M; Mulder EE; Lukkes M; Klaase L; van den Bosch T; van Nimwegen M; Lau SP; Latupeirissa K; Schetters S; van Kooyk Y; Boon L; Moyaart A; Mueller YM; Katsikis PD; Eggermont AM; Vroman H; Stadhouders R; Hendriks RW; Thüsen JV; Grünhagen DJ; Verhoef C; van Hall T; Aerts JG Cancer Cell; 2020 Nov; 38(5):685-700.e8. PubMed ID: 33007259 [TBL] [Abstract][Full Text] [Related]
27. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors. Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S Front Immunol; 2021; 12():619209. PubMed ID: 33790893 [TBL] [Abstract][Full Text] [Related]
28. miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma. Nguyen MT; Luo YH; Li AL; Tsai JC; Wu KL; Chung PJ; Ma N Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827646 [TBL] [Abstract][Full Text] [Related]
29. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge. van der Westhuizen A; Lyle M; Graves MC; Zhu X; Wong JWH; Cornall K; Ren S; Pugliese L; Levy R; Majid A; Vilain RE; Bowden NA Cancer Res Commun; 2022 Aug; 2(8):814-826. PubMed ID: 36923309 [TBL] [Abstract][Full Text] [Related]
30. Molecular patterns of resistance to immune checkpoint blockade in melanoma. Lauss M; Phung B; Borch TH; Harbst K; Kaminska K; Ebbesson A; Hedenfalk I; Yuan J; Nielsen K; Ingvar C; Carneiro A; Isaksson K; Pietras K; Svane IM; Donia M; Jönsson G Nat Commun; 2024 Apr; 15(1):3075. PubMed ID: 38594286 [TBL] [Abstract][Full Text] [Related]
31. Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling. Armstrong E; Chiu MKL; Foo S; Appleton L; Nenclares P; Patrikeev A; Mohan N; Mclaughlin M; Bozhanova G; Hoebart J; Roulstone V; Patin E; Pedersen M; Kyula J; Ono M; Errington-Mais F; Bell J; Harrington KJ; Melcher A; Jennings V J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39060020 [TBL] [Abstract][Full Text] [Related]
32. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy. Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595 [TBL] [Abstract][Full Text] [Related]
33. Immunotherapy Resistance by Inflammation-Induced Dedifferentiation. Mehta A; Kim YJ; Robert L; Tsoi J; Comin-Anduix B; Berent-Maoz B; Cochran AJ; Economou JS; Tumeh PC; Puig-Saus C; Ribas A Cancer Discov; 2018 Aug; 8(8):935-943. PubMed ID: 29899062 [TBL] [Abstract][Full Text] [Related]
34. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Cerezo M; Guemiri R; Druillennec S; Girault I; Malka-Mahieu H; Shen S; Allard D; Martineau S; Welsch C; Agoussi S; Estrada C; Adam J; Libenciuc C; Routier E; Roy S; Désaubry L; Eggermont AM; Sonenberg N; Scoazec JY; Eychène A; Vagner S; Robert C Nat Med; 2018 Dec; 24(12):1877-1886. PubMed ID: 30374200 [TBL] [Abstract][Full Text] [Related]
35. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553 [TBL] [Abstract][Full Text] [Related]
36. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. Isaacs J; Anders C; McArthur H; Force J Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085 [TBL] [Abstract][Full Text] [Related]
37. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Hays E; Bonavida B Drug Resist Updat; 2019 Mar; 43():10-28. PubMed ID: 31005030 [TBL] [Abstract][Full Text] [Related]
38. B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy. Zhao Y; Cao Y; Chen Y; Wu L; Hang H; Jiang C; Zhou X Immunology; 2021 Nov; 164(3):507-523. PubMed ID: 34115389 [TBL] [Abstract][Full Text] [Related]
39. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma. Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489 [TBL] [Abstract][Full Text] [Related]
40. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]